
A biotechnology company focused on the research and development of novel immunotherapies for the treatment of cancer.
The best Bull and Bear pitches based on recency and number of recommendations.
There are no pitches that meet the Top Bear criteria. Explain
If this upsets you, start recommending pitches below!
Read the most recent pitches from players about GTOPQ.
Recs
We have a runner!
Recs
Approval of MyVax
Recs
The phase 3 trial results will be available by year end 2007. Past results have shown a cure rate for cancer in excess of 42%. If phase 3 results are the same as phase 2, the FDA will approve. Technonogy should also work on other forms of cancer. Look for buy out by major biotech company if results are good.
Find the members with the highest scoring picks in GTOPQ.
hibetals (91.70) Score: +311.34
The Score Leader is the player with the highest score across all their picks in GTOPQ.
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
---|---|---|---|---|---|---|---|---|---|---|
HAMRKF | 80.87 | 12/20/2007 |
![]() |
5Y | $2.46 | -99.94% | +206.44% | +306.38 | 0 Comment | |
abetens1 | < 20 | 5/11/2007 |
![]() |
5Y | $3.39 | -99.96% | +201.79% | +301.74 | 0 Comment | |
kkozma | 97.85 | 11/30/2007 |
![]() |
NS | $4.11 | -99.96% | +201.72% | +301.69 | 0 Comment | |
mikehav | < 20 | 5/7/2007 |
![]() |
3M | $3.83 | -99.96% | +199.54% | +299.50 | 0 Comment | |
Geezeruk | < 20 | 5/16/2007 |
![]() |
3W | $3.69 | -99.96% | +198.79% | +298.75 | 0 Comment | |
hibetals | 91.70 | 5/17/2007 |
![]() |
NS | $3.54 | -99.96% | +198.23% | +298.19 | 0 Comment | |
BetterMoney77 | < 20 | 12/12/2007 |
![]() |
NS | $3.29 | -99.95% | +196.48% | +296.44 | 0 Comment | |
jporter34 | < 20 | 6/18/2007 |
![]() |
1Y | $3.68 | -99.96% | +193.39% | -293.35 | 0 Comment | |
Xcentric1 | < 20 | 5/29/2007 |
![]() |
3M | $3.75 | -99.96% | +197.60% | -297.56 | 0 Comment | |
nguyenvanh | < 20 | 7/2/2007 |
![]() |
1Y | $3.89 | -99.96% | +198.26% | -298.22 | 1 Comment |
See what the Wall Street professionals think, according to their public statements and filings.